Floatz logo

Brentuximab Vedotin

Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma

Seagen Inc.antibody_drug_conjugatePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

317 Active assets in the Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Brentuximab Vedotin is also rated in:

T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
anaplastic large cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →